A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models

por Amaral, Robson, Zimmermann, Maike, Ma, Ai-Hong, Zhang, Hongyong, Swiech, Kamilla, Pan, Chong-Xian
Publicado 2020

Oncomir miR-125b Suppresses p14(ARF) to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer

por Amir, Sumaira, Ma, Ai-Hong, Shi, Xu-Bao, Xue, Lingru, Kung, Hsing-Jien, deVere White, Ralph W.
Publicado 2013

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells

por Gheibi, Pantea, Zeng, Shuxiong, Son, Kyung Jin, Vu, Tam, Ma, Ai-Hong, Dall’Era, Marc A., Yap, Stanley Alexander, de Vere White, Ralph W., Pan, Chong-Xian, Revzin, Alexander
Publicado 2017

Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

por Xiao, Wenwu, Li, Tianhong, Bononi, Fernanda C., Lac, Diana, Kekessie, Ivy A., Liu, Yanlei, Sanchez, Eduardo, Mazloom, Anisha, Ma, Ai-hong, Lin, Jia, Tran, Jimmy, Yang, Kevin, Lam, Kit S., Liu, Ruiwu
Publicado 2016

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer

por Steele, Thomas M., Tsamouri, Maria Malvina, Siddiqui, Salma, Lucchesi, Christopher A., Vasilatis, Demitria, Mooso, Benjamin A., Durbin-Johnson, Blythe P., Ma, Ai-Hong, Hejazi, Nazila, Parikh, Mamta, Mudryj, Maria, Pan, Chong-xian, Ghosh, Paramita M.
Publicado 2023

CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors

por Guo, Wenchang, Liu, Ruiwu, Bhardwaj, Gaurav, Ma, Ai-Hong, Changou, Chun, Yang, Joy C., Li, Yuanpei, Feng, Caihong, Luo, Yan, Mazloom, Anisha, Sanchez, Eduardo, Wang, Yan, Huang, Wenzhe, Patterson, Randen, Evans, Christopher P., Lam, Kit S., Kung, Hsing-Jien
Publicado 2013

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

por Wang, Minan, Yao, Li-Chin, Cheng, Mingshan, Cai, Danying, Martinek, Jan, Pan, Chong-Xian, Shi, Wei, Ma, Ai-Hong, De Vere White, Ralph W., Airhart, Susan, Liu, Edison T., Banchereau, Jacques, Brehm, Michael A., Greiner, Dale L., Shultz, Leonard D., Palucka, Karolina, Keck, James G.
Publicado 2018

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

por Rehman, Hasibur, Chandrashekar, Darshan S., Balabhadrapatruni, Chakravarthi, Nepal, Saroj, Balasubramanya, Sai Akshaya Hodigere, Shelton, Abigail K., Skinner, Kasey R., Ma, Ai-Hong, Rao, Ting, Agarwal, Sumit, Eich, Marie-Lisa, Robinson, Alyncia D., Naik, Gurudatta, Manne, Upender, Netto, George J., Miller, C. Ryan, Pan, Chong-xian, Sonpavde, Guru, Varambally, Sooryanarayana, Ferguson, James E.
Publicado 2022

Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment

por Zhang, Lu, Bo, Ruonan, Wu, Yi, Li, Longmeng, Zhu, Zheng, Ma, Ai-Hong, Xiao, Wenwu, Huang, Yanyu, Rojalin, Tatu, Yin, Xingbin, Mao, Chunping, Wang, Fengyi, Wang, Yongheng, Zhang, Hongyong, Low, Kelmen E., Lee, Kiana, Ajena, Yousif, Jing, Di, Zhang, Dalin, Baehr, Christopher M., Liu, Ruiwu, Wang , Lei, Li , Yuanpei, Lam, Kit S.
Publicado 2022